When to Increase Your Tirzepatide Dose — and When to Wait

What the SURMOUNT trial schedule actually showed

The SURMOUNT-1 trial, published in the New England Journal of Medicine and the basis for NICE's recommendation of tirzepatide (TA1026), used a structured four-weekly titration: participants moved from 2.5 mg through 5, 7.5, 10, and 12.5 mg to a 15 mg maintenance dose, with each step taken after roughly four weeks at the previous level. The trial reported average body-weight reductions of around 20–21% at 15 mg over 72 weeks. What the trial design also shows, though, is that the titration was always managed by clinicians, participants who could not tolerate a step could remain at their current dose rather than push upward. That flexibility is deliberate. The schedule is a framework, not a fixed timetable.

The clinical guidance on when to increase a Mounjaro dose consistently makes the same point: the four-week interval is a minimum between steps, not a requirement to move up at exactly week four. Your prescriber weighs your response at the current dose, your side-effect picture, and any evidence of ongoing weight loss before deciding whether an increase is appropriate. The dose ladder exists to maximise efficacy while keeping tolerability high, both matter.

Practical signals that suggest you may be ready for an increase

There is no single test that tells you a higher dose is due, but a few observable patterns tend to inform the conversation with your prescriber. First, side effects from your current dose should have settled. Nausea, loose stools, and reduced appetite are common in the first one to two weeks after starting or increasing tirzepatide; if those are still pronounced at week three or four, asking for an increase early is unlikely to go well. Give your system time to adjust.

Second, consider whether appetite suppression feels noticeably weaker than it did in the first couple of weeks on this dose. Some patients find that the appetite-reducing effect becomes less pronounced after a month (a phenomenon sometimes described as the dose 'wearing in') and that is one reasonable prompt to discuss how to increase your tirzepatide dose with your prescriber. Third, weight loss may have plateaued at the current dose despite sticking to dietary and activity changes. A quick habit worth building: weigh yourself on the same scales, at the same time of day, once a week, and note the number. Four or more weeks of the same reading, combined with settled side effects, gives your prescriber useful evidence to work with.

Explore the factors behind how to know when a Mounjaro dose increase is warranted for a fuller breakdown of what to bring to your clinical review.

When waiting (or not increasing at all) is the right call

Not every patient reaches 15 mg, and that is fine. The licensed goal is the highest dose you tolerate well, which for some people is 7.5 mg or 10 mg. Pushing past a dose that is working, simply because a higher one exists, does not automatically produce better results and may just produce more side effects. The SmPC for tirzepatide, available via the electronic Medicines Compendium (eMC), is clear that the maximum dose is 15 mg but does not mandate reaching it.

There are also specific situations where a prescriber will likely recommend staying put: ongoing significant nausea or vomiting that has not settled by week three or four; a recent illness that disrupted dosing; a planned surgical procedure (tell your anaesthetist and surgical team that you are taking tirzepatide well in advance); or a period of high life stress where changes feel poorly timed. None of these are failures, they are normal clinical management. For a fuller look at how dose decisions fit into the broader Mounjaro journey, the guide to going up a dose on tirzepatide covers the conversation to have with your prescriber in practical terms.

On the cost side of things, dose increases affect what you pay month to month; Mounjaro pricing by dose sets out what to expect as you move through the schedule, so there are no surprises.

What happens at a dose-increase review with a registered prescriber

At a regulated UK pharmacy, a dose increase is not automatic. Before your prescriber authorises a move to the next strength, they will typically ask for evidence of your current weight, review how long you have been on the present dose, and consider whether any new symptoms or changes in your health have occurred since your last review. This is the standard that the NHS guidance on tirzepatide aligns with, every clinical decision is individual.

At nume, a GPhC-registered prescriber personally reviews your information before any increase is approved. That review exists precisely to catch situations where moving up would be premature or clinically unsuitable. If you are unsure whether your response to the current dose is enough to warrant a request, the FAQs cover many of the common questions, and our clinical team is available seven days a week for aftercare support. When you are ready to talk through the next step, speak to our prescribers to start that conversation.